Study: GLP-1 Drugs Like Ozempic Linked To Higher Hair Loss Risk

Ozempic and Hair Loss: What a New Study Found

People taking GLP-1 drugs like Ozempic, Wegovy, and Mounjaro may be more likely to end up with a hair loss diagnosis than people on certain other diabetes medications, according to a large new study in the BMJ. Mounjaro, known generically as tirzepatide, works a bit differently since it activates two gut hormone receptors instead of one, but researchers grouped it with the broader GLP-1 category here.

Researchers combed through health records from tens of thousands of adults with type 2 diabetes and found that those on GLP-1 drugs were more likely to be diagnosed with hair loss than those on two other diabetes medications. The study puts real numbers behind what had mostly been scattered patient complaints online. Hair loss doesn’t carry the danger of a heart attack or kidney failure, but for people going through it, that hardly matters. It can hit self-esteem hard, and it’s often the reason someone stops taking a medication that’s otherwise helping them.

First Large Population Study Links GLP-1 Drugs to Hair Loss

Until now, evidence linking GLP-1 drugs to hair loss came mostly from scattered case reports and informal complaints to the FDA, which said in 2023 it was looking into a possible safety concern. This is the first large study the authors could find that puts the question to a systematic test, using health records from Penn Medicine, an academic system covering more than 6.5 million patients around Philadelphia, Delaware, and southern New Jersey.

Nearly 24,000 Patients Compared in Two Real-World Analyses

Since this wasn’t a clinical trial with random assignment, researchers instead combed through years of medical records and built the comparison as carefully as they could to mimic one. They looked at adults with type 2 diabetes who started one of three drug types between 2019 and 2024: GLP-1 drugs, or two other common diabetes drugs called SGLT-2 inhibitors and DPP-4 inhibitors. Nobody with a prior hair loss diagnosis was included. About 12,000 people starting GLP-1 drugs were compared against roughly 15,200 starting SGLT-2 inhibitors, and a separate group of about 12,000 GLP-1 starters was compared against 11,233 starting DPP-4 inhibitors.

Researchers chose other diabetes drugs as the comparison, rather than people on nothing, since patients starting any of these drugs tend to look similar health-wise, then used statistics to smooth out remaining differences, like GLP-1 starters being younger and heavier on average.

GLP-1 Users Faced Up to 68% Higher Hair Loss Risk

After accounting for those differences, people on GLP-1 drugs were about 37% more likely to be diagnosed with hair loss than people on SGLT-2 inhibitors, and about 68% more likely than people on DPP-4 inhibitors. Those numbers sound bigger than they are: even after the increase, only about 7 in 1,000 GLP-1 patients per year ended up with a hair loss diagnosis, versus roughly 4 to 5 in 1,000 on the other drugs. Most cases showed up within the first year, clustering just before the one-year mark.

Most of that added risk traced back to a specific, usually temporary kind of shedding called telogen effluvium, where physical or metabolic stress pushes hair into a resting phase and it falls out more than usual. This kind of hair loss often reverses on its own, though the study didn’t track whether hair actually grew back. A permanent, scarring type of hair loss, and an autoimmune type called alopecia areata, showed no clear link to the drugs.

The pattern held up fairly consistently regardless of a patient’s age, sex, race, weight, or which specific GLP-1 drug they took, though researchers noted some of those breakdowns relied on smaller numbers and should be read cautiously.

Weight Loss, Not Drug Toxicity, Is the Likely Culprit

So why would a diabetes and weight-loss drug cause hair to fall out? The researchers’ best guess isn’t that the drug damages hair follicles directly. It’s simpler: losing weight fast, and eating less along the way, is a known trigger for this kind of temporary shedding. Cutting calories fast can also leave people short on nutrients like iron, zinc, and biotin, which hair needs to grow normally.

That theory lines up with what the study found: the hair loss was mostly the reversible kind, and cases were concentrated in the first year, a stretch when many patients on these drugs are losing weight quickly. Researchers also floated broader hormonal and immune effects as possible secondary factors, though they see weight loss as the likelier explanation.

Doctors Urged to Discuss Hair Loss Before Prescribing

GLP-1 medications still come with real, well-proven benefits for blood sugar and weight, and doctors aren’t suggesting anyone panic. But hair loss matters to patients regardless of how minor it looks on paper, and it can be reason enough to quit a medication that’s working. Their advice: doctors should bring it up before starting patients on these drugs, watch for it in the first year, and make sure patients are eating enough while losing weight.

Since everyone in this study had type 2 diabetes, it’s still an open question whether the same pattern shows up in the far larger group now taking these drugs purely for weight loss.

---

Disclaimer: This article summarizes findings from a peer-reviewed observational study and is intended for general informational purposes only. It is not medical advice. Anyone with concerns about hair loss or their current medications should talk to a doctor before making any changes to treatment.

---

---